Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Pfizer
Latest Articles
Alan Schwartz Makes Guggenheim Partners an M&A Player
David Rothnie
October 7, 2016
Daily Agenda: Oil Prices Fall on Robust Supply
Andrew Barber
August 24, 2016
Daily Agenda: Mixed Signals Complicate Fed Prediction
Andrew Barber
August 22, 2016
U.S. M&A Could Rebound as Companies See Few Other Growth Options
Dan Weil
July 6, 2016
Investing in a Cure for Cancer
Kaitlin Ugolik
June 7, 2016
Perella Weinberg’s Andrew Bednar Drives Stock Exchange Megadeals
David Rothnie
April 19, 2016
Takeover Veteran Paul Taubman Aims High with PJT Partners
David Rothnie
January 19, 2016
Investing in the Health Care Revolution
Kaitlin Ugolik
January 4, 2016
Allergan-Pfizer Merger Gives Pharma a Growth Injection
Anne Szustek
December 16, 2015
Daily Agenda: Commodity Rout Continues
Andrew Barber
November 23, 2015
Daily Agenda: Liquidity Fuels Continuing M&A Boom
Andrew Barber
October 30, 2015
Ben Thorpe Helps Keep Goldman’s Health M&A Franchise in Top Shape
David Rothnie
June 22, 2015
The 2015 Hedge Fund Rising Stars: Monica Lai
Tyler Davies
June 15, 2015
Daily Agenda: Can U.S. Strength Kick-start Global Growth?
Andrew Barber
January 27, 2015
In Event-Driven Strategy Hedge Funds, M&A is the Headliner
David Turner
May 13, 2014
The New Logic of M&A
Joseph G Paul
May 8, 2014
Spurt of Initial Public Offerings Fails to Lift VC-Backed Companies
Udayan Gupta
April 24, 2013
How to Profit from Faster FDA and Better Science
Fran Hawthorne
August 1, 2012
More Articles